Donald R. Fleming, MD

What is the best practice recommendation for nurse-to-patient ratio for patients receiving IL-2?

What data are available concerning inter- and intrapatient variability in the pharmacokinetics of TKIs in chronic myeloid leukemia?

Many patients place too high a value on the effectiveness of tumor markers in demonstrating their posttreatment status. Even after offering a detailed explanation of the true worth of these tests, the author’s patient still wants to know, “Are you going to order my tumor markers?”

Effective weight management can enhance cancer treatment, improve patient outcomes, and reduce incidence of recurrence and mortality. As with encouraging smoking cessation, oncologists should talk to patients about achieving and maintaining a healthy weight.

Clinical trials could benefit from a greater number of participants with a dedicated cooperative network to support rural community cancer centers.

Is sequencing important when administering chemotherapy on the same day?

Is there any benefit to half-strength chemotherapy given to patients experiencing side effects from the drug or due to decreased functional status?

Could a medication indicated for nausea and vomiting in pregnancy resolve the same symptoms in patients undergoing chemotherapy?

What is the preferred delivery protocol for breast cancer adjuvant bisphosphonates?

What is the familial incidence of gallbladder cancer?